Claudia BR Herke MD PC

Az itteni vizsgálatok

Miről szól a helyszín 19 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Tüdőrák5 vizsgálat
• Tripla negatív emlőrák3 vizsgálat
• Vastagbélrák3 vizsgálat
• Áttétes emlőrák2 vizsgálat
• Krónikus limfoid leukémia (CLL)2 vizsgálat
• Melanóma2 vizsgálat
• Mielóma multiplex2 vizsgálat
• Vesedaganat2 vizsgálat
• Akut limfoid leukémia (ALL)1 vizsgálat
• Elhízás1 vizsgálat
• Gyermekkori daganatok1 vizsgálat
• Gyomor- és nyelőcsőrák1 vizsgálat
• és még 8

Fázis

• 3. fázis14 vizsgálat
• 2. fázis3 vizsgálat

Állapot

• Fut, nem toboroz17 vizsgálat
• Lezárult2 vizsgálat

Fő szponzor

• National Cancer Institute (NCI)12 vizsgálat
• ECOG-ACRIN Cancer Research Group4 vizsgálat
• Alliance for Clinical Trials in Oncology1 vizsgálat
• NRG Oncology1 vizsgálat
• SWOG Cancer Research Network1 vizsgálat

Futó vizsgálatok

• Fut, nem toboroz

  Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

  NCT03233711· 3. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment

  NCT03516942· ECOG-ACRIN Cancer Research Group· Forrás

• Fut, nem toboroz

  Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

  NCT02912559· 3. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás

• Fut, nem toboroz

  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

  NCT02785952· 3. fázis· SWOG Cancer Research Network· Forrás

• Fut, nem toboroz

  Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

  NCT02445391· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás

• Fut, nem toboroz

  Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060· 2. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· 3. fázis· NRG Oncology· Forrás

• Fut, nem toboroz

  Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás

• Fut, nem toboroz

  Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282· 3. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

  NCT02196181· 2. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

  NCT02003222· 3. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT02048813· 3. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

  NCT01886872· 3. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

  NCT01863550· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás

• Fut, nem toboroz

  Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

  NCT01575548· 3. fázis· National Cancer Institute (NCI)· Forrás

Lezárt vizsgálatok

• Lezárult

  Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

  NCT02595905· 2. fázis· National Cancer Institute (NCI)· Forrás

• Lezárult

  Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

  NCT02003209· 3. fázis· National Cancer Institute (NCI)· Forrás